Article Text

Download PDFPDF
BIOPSAR study: ultrasound-guided pre-operative biopsy to assess histology of sarcoma-suspicious uterine tumors: a new study protocol
  1. Stamatios Petousis,
  2. Sabrina Croce,
  3. Michel Kind,
  4. Chrysoula Margioula-Siarkou,
  5. Guillame Babin,
  6. Caroline Lalet,
  7. Dennis Querleu,
  8. Anne Floquet,
  9. Marina Pulido and
  10. Frederic Guyon
  1. Institut Bergonie, Bordeaux, France
  1. Correspondence to Dr Stamatios Petousis, 2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Center of Thessaloniki, Greece; petousisstamatios{at}


Background The pre-operative differential diagnosis between a uterine leiomyoma and a sarcoma can be a challenge. Available diagnostic tools have difficulty distinguishing between the two pathologies.

Primary Objective Τo evaluate the possibility of a pre-operative pathological diagnosis of atypical uterine muscle tumors by vaginal ultrasound-guided biopsy (VUGB).

Study Hypothesis Diagnostic performance of ultrasound-guided biopsy will be capable of differentiating a leiomyoma from a sarcoma with a sensitivity of >90%.

Trial Design A prospective multi-center interventional study will be performed at 10 tertiary French centers. Vaginal ultrasound Doppler examination and pelvic magnetic resonance imaging will be performed before surgery. VUGB will then be performed by a specialist radiologist. The biopsy will be obtained by performing transvaginal ultrasound under local anesthesia with lidocaine using a 16G needle. At least 4–5 specimens will be obtained in order to provide a histopathological diagnosis. All patients included in the study will be operated by laparotomy. All patients included in the study will be followed up for the subsequent 3 years according to their pathological results.

Major Inclusion/Exclusion Criteria All patients >35 years old diagnosed with a suspicious uterine tumor will be included.

Primary Endpoint Sensitivity of VUGB on pathological diagnosis.

Sample Size Considering a sensitivity of 90% (H0) as acceptable and a sensitivity of 95% (H1) as excellent, a sample size of 250 evaluable patients will be necessary to achieve 80% statistical power with a 5% type 1 statistical error.

Estimated Dates for Completing Accrual and Presenting Results Accrual will be completed in December 2024 with results presented in December 2029.

Trial Registration Institutional Review Board (Ethic Committee of Paris Ile de France 6) no 2018-A02343-52.

  • uterine neoplasms
  • sarcoma
  • surgical oncology
  • uterus
  • adenosarcoma

Data availability statement

There are no data in this work.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

There are no data in this work.

View Full Text


  • Contributors All authors have performed significant work regarding authorship of the manuscript, design of the study, methodological approach and review of the final manuscript, and they will provide significant assistance in the performance of the study protocol.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.